Methods: Thirty eyes with gross traumatic hyphema were enrolled in this study. The patients were treated with tranexamic acid (5%) eye drop every 6 hours for 5 days. The main outcome measures were best corrected visual acuity (BCVA), Intra-ocular pressure (IOP), day of clot absorption, and rate of rebleeding. These parameters were evaluated daily for 4 days and Inhibitors,research,lifescience,medical thereafter at the 8th and 14th days after treatment. The patients were also compared with two historical control groups of patients (80 eyes) with traumatic hyphema; the first

control group was treated with oral placebo and the other group was treated with oral tranexamic acid at our department. Result: Prior to treatment, the mean logarithm of the minimum angle of resolution (logMAR) BCVA was 0.59±0.62. BCVA was increased to 0.08±0.14 at day 14 (P<0.001) and the mean IOP before treatment was 13.7±3.9 mm Hg, which was reduced Inhibitors,research,lifescience,medical to 11.4±1.8 mm Hg at day 14 (P=0.004). Rebleeding occurred in one (3.3%) patient on the 4th day post treatment. Comparison between the case group and the other two historical control groups with respect to the rebleeding rate demonstrated statistically significant differences between the Inhibitors,research,lifescience,medical case group and the first control group (P=0.008) but no statistically significant differences between the case group and the second control group (P=0.25). Conclusion: Topical tranexamic

acid seems promising in the management of traumatic hyphema. However, the small sample size of the present study precludes the conclusion that topical tranexamic acid can replace the oral tranexamic acid. Keywords: Hyphema, Topical, Tranexamic acid, Management Introduction We aimed to determine the safety and effectiveness of topical tranexamic acid (5%) Inhibitors,research,lifescience,medical in the management of patients with traumatic hyphema. To our knowledge, the present study is the first to evaluate the effectiveness of topical tranexamic acid in the management of patients with hyphema. Hyphema is defined

as bleeding inside the anterior chamber of the eye. It has different etiologies, including trauma, coagulation disorders, herpetic disease, juvenile Inhibitors,research,lifescience,medical xanthogranuloma, retinoblastoma, leukemia, and rubeosis iridis. The most common kinase inhibitor Oligomycin A etiology is ocular trauma, and hyphema occurs usually Dacomitinib in cases of closed as well as open globe injuries.1,2 Traumatic hyphema, regardless of its size, often occurs in young men secondary to injury to the vessels of the peripheral iris or the anterior ciliary body. One of the most important complications of hyphema is rebleeding (secondary hemorrhage), which occurs in 3.5% to 38% (most studies report an Fluoro-Sorafenib incidence of less than 5%) of patients between 2 and 5 days after injury.3 Complications associated with secondary hemorrhage include glaucoma, optic atrophy, corneal blood staining, amblyopia, and posterior/anterior synechia. These complications may lead to surgical intervention.